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Atherosclerosis is a pathologic process occurring within the 
artery, in which many cell types, including T cell, 
macrophages, endothelial cells, and smooth muscle cells, 
interact, and cause chronic inflammation, in response to 
various inner- or outer-cellular stimuli. Atherosclerosis is 
characterized by a complex interaction of inflammation, lipid 
deposition, vascular smooth muscle cell proliferation, 
endothelial dysfunction, and extracellular matrix remodeling, 
which will result in the formation of an intimal plaque. 
Although the regulation and function of vascular smooth 
muscle cells are important in the progression of atherosclerosis, 
the roles of smooth muscle cells in regulating vascular 
inflammation are rarely focused upon, compared to those of 
endothelial cells or inflammatory cells. Therefore, in this 
review, we will discuss here how smooth muscle cells 
contribute or regulate the inflammatory reaction in the 
progression of atherosclerosis, especially in the context of the 
activation of various membrane receptors, and how they may 
regulate vascular inflammation. [BMB Reports 2014; 47(1): 1-7]
THE ROLES OF vSMC IN THE PROGRESSION OF 
ATHEROSCLEROSIS
Atherosclerosis is a complicated chronic inflammatory disease, 
characterized by the development of atheromatous plaque in 
the intimal layer. Currently, the progression of atherosclerosis is 
divided into three stages. The initial step is the initiation of 
atherosclerosis, due to the activation of endothelial cells by 
metabolic risk factors, such as hyperlipidemia, hypertension, or 
pro-inflammatory mediators. The resultant endothelial dysfunc-
tion allows for the blood monocytes to permeate the endothe-
lial cell layer, and infiltrate into the intima and subintima, re-
sulting in phagocytosis of the LDL cholesterol, or oxidized 
phospholipids and foam cell formation. Necrosis of the lipid 
containing foam cells will result in propagation of in-
flammation, as well as coalescence of the lipid contents, result-
ing in necrotic core formation. In the next step, SMCs migrate 
from the media to the intima, proliferate, and form plaque. 
Pidkova and Berliner demonstrated that oxidized phospholi-
pids, called POVPC, lead to vSMC proliferation and apoptosis, 
by inhibiting cellular differentiation at high concentration (1-3). 
Migrated SMCs in intima can produce extracellular matrix 
(ECM), to make a fibrous cap. The last step is thrombosis, and 
rupture of the atherosclerotic plaque. Typically, the thin layer 
of the fibrous cap easily ruptures, in which few SMCs and 
abundant macrophages exist, because inflammatory cells cause 
the death of SMCs, which produce collagen for the fibrous cap 
as a main source (4). Macrophages are observed to induce 
apoptosis of SMCs by the TNF-α/NO signaling pathway, and 
decrease collagen synthesis by the secretion of MMPs, such as 
MMP-9 and MMP-12 (5-7). Subsequently, these series of re-
actions cause diseases, such as myocardial infarction, stroke, or 
congestive heart failure (8).
THE ROLE OF MEMBRANE RECEPTORS OF vSMC IN 
VASCULAR INFLAMMATION
AT1R (Angiotensin II type 1 receptor)
The role of the Renin-Angiotensin system in the pathophysiol-
ogy of cardiovascular diseases has been extensively studied. 
Angiotensin II (Ang II), through their activation of the angio-
tensin type 1 receptor, has been known to play an important 
role in the development of atherosclerosis, as well as cardiac 
dysfunction (9, 10). AT1R was first shown to be expressed in 
vascular smooth muscle cell in 1973 (11). Extensive researches 
have been done regarding the role of Ang II in promoting in-
flammation by increasing oxidative stress, as well as by upregu-
lating various proinflammatory signals, such as RAGE, 
VCAM-1, ICAM-1, and MCP-1 in vSMCs (12). Moreover, Cai et 
al. showed that Ang II-induced proinflammatory signals allow 
monocytes to bind to vSMCs, indicating a highly significant as-
sociation of vSMCs in inflammation (13). Ang II, besides the 
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proinflammatory effect, also induces SMCs proliferation/migra-
tion and hypertrophic response, which can contribute to the 
development of atherosclerosis. However, there are conflicting 
reports on whether the presence of AT1aR activation in the en-
dothelial cells or vSMCs is required for atherosclerosis 
development. In a recent study, AT1aR in endothelial or 
smooth muscle cell was not necessary to induce atherosclerosis 
and abdominal aortic aneurysm in mice having endothelial or 
smooth muscle cell-specific deletion of AT1aR (14). However, 
in another study, endothelial cell-specific deficiency of AT1aR 
showed the attenuation of Ang II-induced ascending aortic 
aneurysm in LDL receptor KO mice (15). ATRs have been ex-
tensively researched, and angiotensin type 1 receptor antago-
nists are being clinically used for the treatment of car-
diovascular disease (16, 17). However, more research needs to 
be done regarding the role of other receptors in the re-
nin-angiotensin system, such as the MAS receptor and angio-
tensin II type 2 receptor, in the pathogenesis of atherosclerosis. 
RAGE (Receptor for advanced glycation end products)
RAGE is a transmembrane receptor, and recognizes various en-
dogenous ligands, including AGE, HMGB1 and S100 proteins, 
as a multi-ligand receptor (18-20). RAGE is a pattern recogniz-
ing receptor that is important in mediating innate immunity. 
RAGE is abdundantly expressed in various tissues, and are 
known to be expressed in endothelial cells and vSMCs (21). 
Since RAGE was first described and demonstrated from car-
diovascular cells (22, 23), many studies have focused on the 
proinflammatory effect of RAGE activation in diabetes and 
atherosclerosis. As direct evidence, soluble RAGE (sRAGE), a 
decoy receptor that blocks RAGE activation, inhibited athero-
sclerotic severity in streptozotocin-induced diabetic ApoE-null 
mice (24). Our recent study has shown that infusion of 
Angiotensin II in ApoE knockout mice results in increased athe-
rosclerosis and overexpression of RAGE activation, a process 
that has been shown to be attenuated by RAGE inhibition (12). 
Studies have shown that ligands of RAGE, such as S100B, 
HMGB1 increase inflammation, and promote atherosclerosis. 
Hayakawa and colleagues showed that the treatment of S100B 
in RAGE-overexpressed SMC cell line was associated with the 
expression of proinflammatory genes, such as MCP-1, IL-6, and 
ICAM-1, and activates mitogen-activated protein kinase and the 
NFκ-B signaling pathway (25). HMGB1, a chromatin structural 
protein that is released extracellularly during tissue necrosis, 
has been shown to trigger inflammation during atherogenesis, 
and amplify inflammatory reaction, through increasing IL-1β, 
an inflammatory cytokine, in vSMCs (26). Recent studies sug-
gest the involvement of new signaling pathways in 
HMGB1-induced inflammation, in which caspase-1 activation 
mediated by active inflammasome, such as NLRP3, results in 
increased IL-1β production and the propagation of 
inflammation. HMGB1 mediated inflammation is mediated 
through various pattern recognizing receptors, including TLR2, 
TLR4, and RAGE (27, 28). Although these results were demon-
strated in other cell types, the involvement of the novel signal-
ing pathway in mediating vascular inflammation is highly 
expected. Since several receptors can interact under in-
flammatory stimuli, researchers have focused on the main re-
ceptors involved in mediating vascular inflammation. Kokkola 
compared the proinflammatory activity among TLR2, RAGE, 
and IL-1 receptor type I using KO mouse, and demonstrated 
that RAGE is the major receptor activated from stimuli in mac-
rophages (29). Although RAGE activation is associated with in-
creased oxidative stress and proinflammatory signaling activa-
tion through NFκB activation, the intracellular signaling cas-
casde for these processes is not well defined. For RAGE inter-
acting adaptor proteins, few molecular mechanisms have been 
elucidated. However, a recent study by Schmidt et al. revealed 
that mDia1, a member of the formin family, binds to cytoplas-
mic domain of RAGE under the activation of S100B, which can 
induce oxidative stress, migration and vascular remodeling, 
through c-Src translocation and Rac1 activation, followed by 
NOX1-PI3K-AKT-GSK3β signaling pathway in SMCs, of the 
wire-injured mouse model (30). A new role of RAGE in vas-
cular osteogenesis has recently been demonstrated, which 
showed that RAGE promotes vascular calcification, through the 
activation of Wnt/β-catenin signaling (31). Another article dem-
onstrates that RAGE can play a crucial role in vascular calcifica-
tion, in peritoneal dialysis patients (32). Although RAGE-ligand 
induced signaling has been implicated in the inflammation as-
sociated with chronic diseases, such as diabetes and athero-
genic process, the physiological roles or signaling pathways in 
vSMCs have still not been fully elucidated.
LOX-1 (lectin-like oxidized LDL receptor)
The importance of LDLR in atherosclerosis has been demon-
strated in the middle of the 1970s (33, 34), from the accel-
erated atherosclerosis found in familial hypercholesterolemia 
patients lacking LDLR. The lack of LDL receptor is associated 
with decreased clearance of LDL in the circulation and hyper-
cholesterolemia, resulting in the accelerated development of 
atherosclerosis. Since then, mouse models of atherosclerosis 
have been developed, by knocking out the LDL receptor in 
mice (35), and LDLR-knockout mice have been widely used to 
study several diseases or symptoms, including atherosclerosis, 
fibrosis, and nephrotic syndrome. In addition, LDLR is also 
known to regulate the amount of apolipoprotein E or amyloid 
β in the brain (36). However, the LDL receptor is not the main 
pathway for the uptake of cholesterol in the arteries, as evi-
denced by the accelerated atherosclerosis in familial hyper-
cholesterolemia (34, 37). In macrophage, LDL needs to be 
modified by oxidization or acetylation for phagocytosis (38). 
The modified LDLs are bound and internalized through 
LOX-1. In vSMCs, overexpression of LOX-1 levels in response 
to ox-LDL results in activation of inflammatory signals, such as 
NF-κB and JNK (39). LOX-1, identified as the major ox-LDL re-
ceptor in endothelial cells, may play a critical role in the ini-
tiation and progression of atherosclerosis, through their uptake 
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of modified LDLs, and activation of the proinflammatory path-
way in vSMCs (40). In vSMCs, proinflammatory cytokines, 
such as TGF-β, IL-1α, and IL-1β, increase LOX-1 expression; 
whereas, LOX-1 inhibition leads to significant reduction in the 
formation of the atherosclerotic lesions (41). Since ox-LDL up-
take through LOX-1 is critical for foam cell formation, which is 
the hallmark of the atherosclerotic region, and vSMCs in in-
timal area highly express LOX-1, some pioneer studies have 
addressed the role of vSMC related to LOX-1. Although these 
studies did not present direct evidence, high possibilities are 
suggested for the transformation from SMCs into foam cells 
though LOX-1 (42, 43). Statins such as pravastatin showed a 
new pleiotropic effect, in which pravastatin downregulated 
LOX-1 expressions in human vSMCs and atherosclerotic le-
sions, and reduced intimal media thickness and lipid core area 
(43). In a study using mice overexpressing LOX-1 from ApoE 
KO background, proatherosclerotic role of LOX-1 was 
demonstrated. Also, a synergistic role with LDLR was sug-
gested from LOX-1 and LDL double knockout mice, in which 
the double knockout mice had a significantly reduced athero-
sclerotic lesion formation, compared to that of LDLR knockout 
mice (44). 
TLRs (Toll-like receptors)
TLRs, one of the well-characterized-pattern-recognition re-
ceptors, are important receptors for mediating innate immunity. 
Around 13 different TLRs have been demonstrated in humans 
and mammals, and exogenous and endogenous ligands have 
been identified for 9 different types of TLRs, in mono-
cytes/macrophages, dendritic cells, T and B lymphocytes, mast 
cells and vascular cells (45). Among the TLRs, increased ex-
pression levels of TLR 2 and 4 have been shown in athero-
sclerotic plaques, and their importance for initiation and pro-
gression have been demonstrated from several studies (46, 47).
　TLR2 is important for the recognition of bacterial lip-
oproteins, and known to promote inflammation in vSMCs, 
which has been demonstrated by previous studies, using apoli-
poprotein E-knockout (ApoE KO) mouse (48-50). Although re-
searches related to TLR2 have been performed in vSMCs, most 
studies focus on the proliferation or migration mechanisms of 
vSMCs, rather than being related to inflammatory response. In 
the case of vSMCs proliferation, TLR2 and TLR4 signaling 
pathway are known to be involved in neointimal lesions under 
HSP60 stimulation (51). According to recent studies, TLR2 can 
activate p38 MAPK, ERK1/2, JNK1/2 and AKT, in vSMCs from 
TLR2 KO mouse. Also, cAMP response element-binding pro-
tein (CREB)-dependent IL-6 production was highly related to 
TLR2, not TLR4, in vSMCs migration (52). Interestingly, Lee et 
al. suggested a new role of TLR2 in vSMCs, where MMP2 and 
proinflammatory cytokines can be produced through 
TLR2-Nox1-dependent manner, leading to increasing mono-
cyte-endothelial cell adhesion, and transendothelial migration 
of monocytic cells (53).
　TLR4 is mainly stimulated by lipopolysaccharide (LPS) in 
vSMCs, and is known to induce inflammatory signals, as well 
as TLR2. Yang and colleagues showed that TLR4 stimulated by 
LPS activated phosphorylation of extracellular regulated kinase 
1/2 (ERK1/2), induced monocyte-chemoattractant protein-1 
(MCP-1) release and interleukin (IL)-6, and increased IL-1α ex-
pression (54). Another research group also examined increased 
TLR4 expression and nitric oxide (NO) production by LPS 
playing very important roles to induce inflammation in human 
aortic vascular SMCs (55). TLR4 can increase MMP-9 ex-
pression, which is known to be involved in the pathogenesis 
of atherosclerotic plaque instability, as well as abnormal arte-
rial remodeling. Li et al. demonstrated that TLR4/NF-κB path-
way, stimulated by LPS, was able to increase the expression of 
MMP-9 mRNA and protein for human aortic vascular SMCs 
migration, indicating a high possibility for the correlation be-
tween TLR4/NF-κΒ pathway, and pathogenesis of athero-
sclerosis (56). Up to date, studies have demonstrated that TLR2 
and TLR4 share common pathways, or have synergetic effects 
in the inflammatory signaling. However, recent study sug-
gested that TLR4 has a protective role in atherosclerosis pro-
gression, whereas TLR2 has a proinflammatory response, fol-
lowed by periodontal pathogen (57). Therefore, further 
in-depth researches are needed to understand the differing 
roles of TLR4 in vascular inflammation. 
NLRs (Nod-like receptors)
NLRs are another type of cytoplasmic pattern-recognition re-
ceptors, which play important roles in innate immunity (58). 
Among members of the NLRs family, NLRP3 is the receptor 
studied most extensively for its association with cardiovascular 
diseases, such as cardiomyopathy and heart failure (59). 
Microbial molecules or endogenous danger signals can activate 
NLRP3, and in turn, NLRP3 recruits and makes a complex with 
apoptosis-associated speck-like protein (ASC), and pro-cas-
pase-1 (60). This complex is called an active NLRP3 in-
flammasome, which activates caspase-1, IL-1β, and IL-18. 
NLRP3 is also involved with autophagy, which is a quality con-
trol system by degradation or re-use of intracellular organelles 
and proteins, and is essential for cell survival (61). NLRP3 in-
flammasome was reported to co-localize with autophagosome, 
as autophagy mechanism can regulate inflammasome activa-
tion, through the interaction between autophagic adaptor p62 
and ASC (62). Another study demonstrated the importance of 
this relationship, by showing that LPS induces more mortality, 
through the active NLRP3 inflammasome in autophagy-defi-
cient (LC3B-deficient) mouse model (63). New roles of NLRP3 
have been elucidated, with regard to the pathogenesis of car-
diovascular diseases. In human coronary atherosclerosis, 
NLRP3 was reported to have a positive correlation with an in-
creased epicardial adipose tissue volume, which has been 
shown to be associated with increased cytokine production and 
proatherogenesis (64). In heart from NLRP3 KO mice, the pro-
tective effect of ischemic preconditioning is increased against 
ischemia-reperfusion injury, through the reduced expression of 
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Fig. 1. Involvement of vSMCs in the 
inflammatory response of atheroscle-
rosis. 1-5 briefly show LDL-induced 
inflammatory reactions, in which 
modified LDL particles are accumu-
lated in the artery under various risk 
factors, resulting in the formation of 
form cells. This process is mediated 
by uptake of ox-LDL particles from 
the activation of scavenger receptors 
of macrophages, such as CD36, 
SRA1/2, LOX-1, and TLRs. In addition, 
SMCs can produce proinflammatory 
cytokines, through the activation of 
LOX-1, RAGE, TLR2, TLR4, AT1R, or 
NLRP3 by their specific agonists, and 
by their interaction with endothelial 
cells and macrophages.
STAT3 (65). There are some debates as to whether NLRP3 in-
flammasome is involved in the progression of atherosclerosis, 
or not. In the LDLR KO-diabetic mice model, activation of 
NLRP3 inflammasome with increased inflammatory responses, 
as well as IL-1β production, has been demonstrated in the athe-
rosclerotic lesions (66). On the other hand, NLRP3 did not 
show any difference from ApoE KO and NLRP3-/ApoE-double 
KO mice study (68). Nevertheless, recent studies strongly sug-
gest the involvement of NLRP3 inflammasome in atheros-
clerosis. Qial et al. showed that activated NF-κB due to TLR4 
activation can bind to the NLRP3 promoter, resulting in the in-
crease of NLRP3 expression from macrophages (67). Xiao et al. 
also demonstrated that sterol regulatory element binding pro-
tein 2 (SREBP2) overexpress NLRP3, which results in endothe-
lial inflammation, and atherosclerosis formation. SREBP2, as an 
initial activator, was able to be activated in endothelial cells by 
atheroprone arterial blood flow, leading to NLRP3 inflamma-
some activated IL-1β signaling, followed by subsequent activa-
tion of NADPH oxidase2 (NOX2), in the area of atherosclerotic 
lesions (69). In a study regarding the role of NLRP3 within 
vSMCs in mediating inflammation during atherogenesis, Xiao et 
al. demonstrated that NLRP3 activation due to atheroprone 
blood flow is important for inflammation and progression of 
atherosclerosis. As disturbed arterial blood flow has been 
known to induce phenotypic changes in vSMCs that are highly 
involved in inflammatory reaction through the overexpression 
of receptors affecting inflammation and adhesion, we speculate 
that NLRP3 may have an important role in mediating activation 
of vSMCs in atherogenesis (70, 71).
CONCLUSIONS
Until recently, vSMCs had been considered to passively trans-
form or differentiate into form cells, by factors from macro-
phage stimulation. However, recent studies have focused on 
the active roles of vSMCs in propagating inflammation, during 
the development of atherosclerosis. In this review, we sum-
marized the possible role of vSMCs in actively mediating in-
flammation, through their regulation of cytokine secretion and 
membrane receptors, during the pathogenesis of atheroscle-
rosis (Fig. 1). 
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